Hepatitis C infection, an overview;Hepatitis C-virus-infektion ubersicht

Praxis

Volumn 89, Issue 40, 2000, Pages 1587-1604

  Grob, P J ^b   Negro, F ^b,b   Renner, E L ^b,b   Burckhardt, J J ^b   Burkardt, H J ^b   Cathomas, G ^b   Cerny, A ^b   Dufour, J F ^b   Erb, P ^b   Fierz, W ^b   Flepp, M ^b   Francioli, P ^b   Frey, R ^b   Frey Wettstein, M ^b   Gonvers, J J ^b   Gorgiewski, M ^b   Hadengue, A ^b   Hammig R ^b   Heim, M ^b   Heimgartner, M ^b   Herzog, Ch ^b   Huch, A ^b   Joller, H I ^b   Kammerlander, R ^b   Lavanchy, D ^b   Mantegani, A ^b   Matter, L ^b   Mean F ^b   Meili, D ^b   Meyenberger, Ch ^b   Meyer Wyss, B ^b   Michel, G ^b   Pantaleo, G ^b   Perrin, L ^b   Pfaffli P ^b   Piffaretti, J C ^b   Pirovino, M ^b   Raeber, P A ^b   Reichen, J ^b   Rickenbach, M ^b   Siegl, G ^b   Steffen, R ^b   Steurer, J ^b   Weitz, M ^b   Zehnder, A ^b   Zimmermann, A ^b   Odenheimer, E ^a   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Diagnostic; Epidemiology; Hepatitis C virus; Pathophysiology; Therapy

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; RIBAVIRIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ANTIBODY DETECTION; CHRONIC HEPATITIS; COMORBIDITY; CYTOPATHOGENIC EFFECT; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; ONSET AGE; PREVALENCE; REVIEW; SCREENING TEST; SEX RATIO; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL;

EID: 19244371469     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Alter MJ.: Epidemiology of hepatitis C. Hepatology 26 (Suppl 1), 62S-65S, 1997.
2. Alter MJ., Kruszon-Moran D., Nainan OV., McQuillan GM., Gao F., Moyer LA., Kaslow RA., Margolis HS.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med, 341, 556-562, 1999.
3. Maertens G., Stuyver L.: HCV genotyping by the Line Probe Assay INNOLiPA HCV II. In: Hepatitis C protocols. Lau J.Y.N., ed. Humana Press Inc. Totowa, NJ, pp. 183-198, 1998.
4. Davidson F., Simmonds P., Ferguson JC., Jarvis LM., Dow BC., Follett EAC., Seed CRG., et al.: Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol, 76, 1197-1204, 1995.
5. Rubbia-Brandt L., Quadri R., Abid K., Giostra E., Zarski JP., Spahr L., Male PJ., Mentha G., Borisch B., Hadengue A., Negro F.: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol, 33, 106-115, 2000.
6. Arichi T., Saito T., Major ME., Belyakov IM., Shirai M., Engelhard VH., Feinstone SM., Berzofsky JA.: Prophylactic DNA vaccine for hepatitis C virus (HCV) injection: HCV-specific cytoloxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A, 97, 297-302, 2000.
7. Battegay M., Fikes J., Di Bisceglie AM., Wentworth PA., Sette A., Celis E., Ching W.: Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol, 69, 2462-2470, 1995.
8. Battegay M.: Immunity to hepatitis C virus: a further piece of the puzzle. Hepatology, 24, 961-963, 1996.
9. Cacciarelli TV., Martinez OM., Gish RG., Villanueva JC., Krams SM.: Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology, 24, 6-9, 1996.
10. Cerny A., McHutchison JG., Pasquinelli C., Brown ME., Brothers MA., Grabsceid B., Fowler P., Houghton M., Chisari FV.: Hepatitis C virus specific cytotoxic T cell response: identification of multiple HLA-A2 restricted epitopes. J Clin Invest, 95, 521-530, 1995.
11. Kita H., Moriyama T., Kaneko T., Harase I., Nomura M., Miura H., Nakamura I, Yazaki Y., Imawari M.: HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology, 18, 1039-1044, 1993.
12. Forns X., Purcell RH., Bukh J.: Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol, 7, 402-410, 1999.
13. Forns X., Emerson SU., Tobin GJ., Mushahwar IK., Purcell RH., Bukh J.: DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine, 17, 1992-2002, 1999.
14. Friedman SL.: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 275, 2247-2250, 2000.
15. Gale M Jr., Kwieciszewski B., Dossett M., Nakao H., Katze MG.: Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol, 73, 6506-6516, 1999.
16. Heim MH., Moradpour D., Blum HE.: Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol , 73, 8469-8475, 1999.
17. Koziel MJ., Dudley D., Wong JT., Dienstag J., Houghton M., Ralston R., Walker BD.: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol, 149, 3339-3344, 1992.
18. Koziel MJ., Dudley D., Afdhal N., Choo QL., Houghton M., Ralston R., Walker BD.: Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol, 67, 7522-7532, 1993.
19. Marusawa H., Hijikata M., Chiba T., Shimotohno K.: Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol, 73, 4713-4720, 1999.
20. Ning Q., Brown D., Parodo J., Cattral M., Gorczynski R., Cole E., Fung L., Ding JW., Liu MF., Rotstein O., Phillips MJ., Levy G.: Ribavirin inhibits viral-induced macrophage production of TNF, IL-I. the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol, 160, 3487-3493, 1998.
21. Shi Z., Wakil AE., Rockey DC.: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A, 94, 10663-10668, 1997.
22. Shirai M., Okada H., Nishioka M., Akatsuka T., Wychowski C., Houghten R., Pendleton CD., Feinstone SM., Berzofsky JA.: An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol, 68, 3334-3342, 1994.
23. Sobesky R., Mathurin P., Charlotte F., Moussalli J., Olivi M., Vidaud M., Ratziu V., Opolon P., Poynard T.: Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology, 116, 378-386, 1999.
24. Wang H., Eckels DD.: Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. J Immunol, 162, 4177-4183, 1999.
25. Weiner A., Erickson AL., Kansopon J., Crawford K., Muchmore E., Hughes AL., Houghlon M., Walker CM.: Persistent hepatitis C virus infection in a chimpaneez is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A, 92, 2755-2759, 1995.
26. Takano S., Satomura Y., Omata M.: Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology, 107, 805-811, 1994.
27. Alberti A., Morsica G., Chemello L., Cavalletto D., Noventa F., Pontisso P., Ruol A.: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet, 340, 697-698, 1992.
28. Mathurin P., Moussalli J., Cadranel JF., Thibault V., Charlotte F., Dumouchel P., Cazier A., Huraux JM., Devergie B., Vidaud M., Opolon P., Poynard T.: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology, 27, 868-872, 1998.
29. Prieto M., Olaso V., Verdu C., Cordoba J., Gisbert C., Rayon M., Carrasco D., Berenguer M., Higon MD., Berenguer J.: Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology, 22, 413-417, 1995.
30. Grob PJ., Pontisso P.: Does the healthy carrier of HCV exist? In: Viral hepatitis and liver disease, Mario Rizzetto et al. Edizioni Minerva Medica, 879-887, 1997.
31. 31a. Seeff LB., Buskell-Bales Z., Wright EC., Durako SJ., Alter HJ., Iber FL., Hollinger FB., Gitnick G., Knodell RG., Perrillo RP., et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis The National Heart, Lung, and Blood Institute Study Group. N Engl J Med, 327, 1906-1911, 1992.
32. 31b. Seeff LB., Miller RN., Rabkin CS., Buskell-Bales Z., Stratey-Eason KD., Smoak BL., Johnson LD., Lee SR., Kaplan EL.: 45 year fellow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med., 132, 105-111, 2000.
33. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., Nevens F., Solinas A., Mura D., Brouwer JT., Thomas H., Njapoum C., Casarin C., Bonetti P., Fuschi P., Basho J., Tocco A., Bhalla A., Galassini R., Noventa F., Schalm SW., Realdi G.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112, 463-472, 1997.
34. Hopf U., Moller B., Kuther D., Stemerowicz R., Lobeck H., Ludtke-Handjery A., Walter E., Blum HE., Roggendorf M., Deinhardt F.: Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol, 10, 69-76, 1990.
35. Di Bisceglie AM., Goodman ZD., Ishak KG., Hoofnagle JH., Melpolder JJ., Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology, 14, 969-674, 1991.
36. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero ML., Realdi G.: Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol, 16, 273-281, 1992.
37. Koretz RL., Abbey H., Coleman E., Gitnick G.: Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 119, 110-115, 1993.
38. Mattsson L., Sonnerborg A., Weiland O.: Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver, 13, 274-278, 1993.
39. Takahashi M., Yamada G., Miyamoto R., Doi T., Endo H., Tsuji T.: Natural course of chronic hepatitis C. Am J Gastroenterol, 88, 240-243, 1993.
40. Yano M., Yatsuhashi H., Inoue O., Inokuchi K., Koga M.: Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut, 34 (2 Suppl), 13-16, 1993.
41. Roberts JM., Searle JW., Cooksley WG.: Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn, 28 (Suppl 5), 37-41, 1993.
42. Tong MJ., el-Farra NS., Reikes AR., Co RL.: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med, 332, 1463-1466, 1995.
43. Kenny-Walsh E.: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med, 340, 1228-1233, 1999.
44. Grob PJ, and a working group of the Federal Office of Health and SEVHEP: Infektionen mit dem Hepatitis C Virus - Epidemiologie, Prävention und Behandlung. Bulletin BAG, 49, 2-12, 1998.
45. Poynard T., Bedossa P., Opolon P.: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINlVlR, and DOSVIRC groups. Lancet, 349, 825-832, 1997.
46. Benvegnu L., Fattovich G., Noventa F., Tremolada F., Chemello L., Cecchetto A., Alberti A.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer, 74, 2442-2448, 1994.
47. Alberti A., Pontisso P., Chemello L., Fattovich G., Benvegnu L., Belussi F., De Mitri MS.: The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol, 22, 38-41, 1995.
48. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando ME., Raimondo G.: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med, 341, 22-26, 1999.
49. Opravil M., Hunziker R., Luthy R., Grob PJ.: Chronic hepatitis B and C in HIV-infected patients. Dtsch Med Wochenschr, 123, 753-760, 1998.
50. Soto B., Sanchez-Quijano A., Rodrigo L., del Olmo JA., Garcia-Bengoechea M., Hernandez-Quero J., Rey C., Abad MA., Rodrigue: M., Sales Gilabert M., Gonzalez F., Miron P., Caruz A., Relimpio F., Torronteras R., Leal M., Lissen E.: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatology, 26, 1-5, 1997.
51. Telfer P., Sabin C., Devereux H., Scott F., Dusheiko G., Lee C.: The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol, 87, 555-561, 1994.
52. Vogt M., Lang T., Frosner G., Klingler C., Sendl AF., Zeller A., Wiebecke B., Langer B., Meisner H., Hess J.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med, 341, 866-870, 1999.
53. Mondelli MU., Silini E.: Clinical significance of hepatitis C virus genotypes. J Hepatol, 31(Suppl 1), 65-70, 1999.
54. Benvegnu L., Pontisso P., Cavalletto D., Noventa F., Chemello L., Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology, 25, 211-215, 1997.
55. Khan MH., Farrell GC., Byth K., Lin R., Weltman W., George J., Samarasinghe D., Kench J., Kaba S., Crewe E., Liddle C.: Which patients with hepatitis C develop liver complications? Hepatology, 31, 513-520, 2000.
56. Hirsch KR., Wright TL.: «Silent Killer» or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology, 31, 536-537, 2000.
57. Burckhardt JJ., Deiss V., Senn M., Edward A., Cerutti JA.: Anti-HCV underestimates the prevalence of hepatitis C virus in end stage renal disease patients. Schweiz. med. Wschr., 124, Suppl. 50/II, 9, 1993.
58. Blumberg A., Zehnder C., Burckhardt JJ.: Prevention of hepatitis C infection in haemodialysis units. A prospective study. Nephrol Dial Transplant, 10, 230-233, 1995.
59. Reichen J.: Persönliche Mitteilung in http://www.cx.unibe.ch/ikp/lab2/HCVCRF.html
60. Hofer M. Joller-Jemelka HI., Grob PJ., Lüthy R., Opravil M. and the Swiss HIV Cohort Study: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Microbiol Infect Dis, 17, 6-13, 1998.
61. Jilg W., Sieger E., Zachoval R., Schätzle H.: Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol, 23, 14-20, 1995.
62. Grob PJ., Jilg W., Bornhak H., Gerken G , Gerlich W., Günther S., Hess G., Hüdig H., Kitchen A., Margotis H., Michel G., Trepo C., Will H., Zanetti A., Mushahwar I.: The serological pattern «anti-HBc alone». J Med Virol. (in press), 2000.
63. Burckhardt JJ.: Assessment of needs for plasma for fractionation in Europe. Biologicals, 27, 337-341, 1999.
64. Schlaak JF., Trippler M., Ernst I. et al.: Chronic hepatitis C: the viral load per liver cell before treatment as a new marker to predict long-term response to IFN-therapy. J Hepatol, 27, 917-921, 1997.
65. Cathomas G., Renner E.L., Leberbiospie heute. Schweizerische Ärztezeitung, 80:Nr.39, 2355-2361, 1999
66. Ware JE.Jr., Bayliss MS., Mannocchia M., Davis GL.: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology, 30, 550-555, 1999.
67. Shahin M., Schuppan D., Waldherr R., Risteli J., Risteli L., Savolainen ER., Oesterling C., Abdel Rahman HM., el Sahly AM., Abdel Razek SM., et al.: Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology, 15, 637-644, 1992.
68. Ninomiya T., Yoon S., Hayashi Y., Sugano M., Kumon Y., Seo Y., Shimizu K., Kasuga M.: Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol, 13, 68-74, 1998.
69. Oberti F., Valsesia E., Pilette C., Rousselet MC., Bedossa P., Aube C., Gallois Y., Rifflet H., Maiga MY., Penneau-Fontbonne D., Cales P.: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology, 113, 1609-1616, 1997.
70. Wang VS., Hughes V., Trull A., Wight DG., Petrik J., Alexander GJ.: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat, 5, 187-192, 1998.
71. Wiese M., Berr F., Lafrenz M., Porst H., Oesen U. for the East German Hepatitis C Study Group: Low frequency of cirrhosis in an hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology, 32, 91-96, 2000.
72. Vogel W.: Treatment of acute hepatitis C virus infection. J Hepatol 31 (suppl 1), 189-192, 1999.
73. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., Shiomi S., Seki S., Kobayashi K., Otani S.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346, 1051-1055, 1995.
74. Schweizerische Expertengruppe für virale Hepatitis (SEVHEP), Schweizerische Gesellschaft fur Gastroenterologie und Hepatologie (SGGH), Swiss Association for the Study of the Liver (SASL). Empfehlungen für die Therapie der chronischen Hepatitis C mit Interferon.: Schweiz Ärztezeitung, 77, 1744-1745, 1996.
75. SASL, SEVHEP, SGGH, FAGAS. Empfehlungen zur Therapie der chronischen Hepatitis C.: In press, 2000.
76. Chemello L., Cavalletto L., Casarin C., Bonetti P., Bernardinello E., Pontisso P., Donada C., Belussi F., Martinelli S., Alberti A.: Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Ann Intern Med, 124, 1058-1060, 1996.
77. Gavier B., Martinez-Gonzalez MA., Riezu-Boj et al.: Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterohgy, 113, 1647-1653, 1997.
78. McHutchison JG., Gordon SC., Schiff ER., Shiffman ML., Lee WM., Rustgi VK., Goodman ZD., Ling MH., Cort S., Albrecht JK. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med, 339, 1485-1492, 1998.
79. Poynard T., Marcellin P., Lee SS., Niederau C., Minuk GS., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet, 352, 426-1432, 1998.
80. Poynard T., McHutchison J., Goodman Z., Ling MH., Albrecht J.: Is an «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology, 31, 211-218, 2000.
81. Reichard O., Glaumann H., Fryden A., Norkrans G., Wejstal R., Weiland O.: Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol, 30, 783-787, 1999.
82. Reichen J. Solioz M., Buhler H., Gonvers JJ., Knoblauch M., Lavanchy D., Male PJ., Meyer B., Schmid M., Bianchi L.: Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial. Clin Investig, 71, 888-893, 1993.
83. Reichen J., Bianchi L., Frei PC., Male PJ., Lavanchy D., Schmid M.: Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. J Hepatol, 20, 168-174, 1994.
84. Reichen J., Bianchi L., Buhler H., Dolivo N., Gonvers JJ., Lavanchy D., Male PJ., Renner EL., Solioz M., Schmid M., Zimmermann A.: Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. J Hepatol, 25, 275-282, 1996.
85. Renner-Schneiter EC., Dufour JF., Fried R., Gonvers JJ., Knoblauch M., Male PJ., Negro F., Reichen J., Rohner C., Steuerwald M., Renner EL. The combination of daily interferon-alpha (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C: initial response and tolerability (abstract). Hepatology, 30, 201A, 1999.
86. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Maromo F., Sato C.: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med, 334, 77-81, 1996.
87. Hirashima N., Mizokami M., Onto E., Koide T., Itazu I., Kumada K., Sakakibara K., Kano H., Lau JY.: Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol, 11, 955-958, 1996.
88. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., Iijima A., Urushihara A., Kiyosawa K., Okuda M., Hino K., Okita K.: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatohgy, 27, 1394-1402, 1998.
89. Yamaguchi K., Omagari K., Kinoshita H., Yoshioka S., Furusu H., Takeshima F., Nanashima A., Yamaguchi H., Kohno S.: Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J Clin Gastroenterol, 29, 207-209, 1999.
90. Bennett WG., Inoue Y., Beck JR., Wong JB., Pauker SG., Davis GL.: Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med, 127, 855-865, 1997.
91. Kim WR., Poterucha JJ., Hermans JE., Therneau TM., Dickson ER., Evans RW., Gross JB Jr.: Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med, 127, 866-874, 1997.
92. Koff RS.: Cost-effectiveness of treatment for chronic hepatitis C. J Hepatol. 31 (Suppl 1), 255-258, 1999.
93. Younossi ZM., Singer ME., McHutchison JG., Shermock KM.: Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology, 30, 1318-1324, 1999.
94. Ridzon R., Gallagher K., Ciesielski C., Mast EE., Ginsberg MB., Robertson BJ., Luo C-C., DeMaria A.: Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. New England Journal of Medicine, 336, 919-922, 1997.
95. Thomas DL., Zenilman JM., Alter HJ. et al.: Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore. An analysis of 309 sex partnerships. J Infect Dis. 171, 768-775, 1995.
96. Chayama K., Kobayashi M., Tsubata A., Koida I., Arase Y., Saitoh S., Ideda K., Kumada H.: Molekular analysis of intrapousal transmission of hepatitis C virus. J Hepatol, 22, 431-439, 1995.
97. Piazza M., Sagliocca L., Tosone G.: Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. Arch Int Med, 157, 1537-1544, 1997.
98. Mazza C., Ravaggi A., Rodella A., Padula D., Duse M., Lomini M., Puoti M., Rossini A., Cariani E., and the Study Group for Vertical Transmission: (1998). Prospective Study of Mother-to-Infant Transmission of Hepatitis C virus (HCV) infection. Journal of Medical Virology, 54, 12-19, 1998.
99. Thomas SL., Newell M-L.,Peckham CS., Ades AE., Hall AJ.: A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. International Journal of Epidemiology, 27, 108-117, 1998.
100. BAG/OFSP: Hépatites aiguës déclarées en Suisse en 1994-1995. Bull OFSP, 16, 4-8, 1997 und persönliche Mitteilung R. Kammerlander (BAG).
101. Grob PJ., Joller-Jemelka HJ.: Hepatitis C virus (HCV), anti-HCV and non-A, non-B hepatitis. Schweiz Med Wochenschr, 120, 117-124, 1990.
102. Zufferey Ch., Lavanchy D., Reiff M., Schneider Ph., Frei Ph., Pécoud A., Gonvers JJ.: Prévalence de l'anticorps anti-HCV (C100-3) chez 20' 373 donneurs de sang. Schweiz, med. Wschr., 122, 1524-1529, 1992.
103. Tullen E., De Saussure Ph., Saussuer-Lauper M.: Facteurs de risque, ALAT et RNA viral chez 68 donneurs de sang avec anticorps anti-hépatite C. Schweiz. med. Wschr., 123, 57-61, 1993.
104. Burckhardt JJ., Bachmann P.: Seroprävalenz von Infektionserregern bei Blutspendern in der Schweiz: wie gross ist das Restrisiko? Klin. Lab., 38, 380-384, 1992.
105. Burckhardt JJ.: Fünf Jahre Anti-HCV Screening- sechs Jahre HCV. Haemo, 4-7, 10, 1995.
106. Perret BA., Senn M., Affentranger P., Poorbeik M., Burckhardt JJ., Morell A.: Hepatitis-C-Virus-Serostatus der Hämophilen in der Schweiz. Schweiz. med. Wschr., 123, 79-81, 1993.
107. Scheitlin Th., Joller-Jemelka HI., Grob PJ.: Hepatitis und HIV-Infektionen bei Benützern und Benützerinnen illegaler Drogen. Schweiz med. Wschr., 122, 643-645, 1992.
108. Steffen Th., Gutzwiller F.:Hepatitis B and C bei intravenös Drogenkonsumierenden in der Schweiz. Praxis, 88, 1937-1944, 1999.
109. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., Cristianini G., the Dyonisos Study Group. Prevalence of chronic liver disease in the general population of Northern Italy: the Dyonisos Study. Hepatology, 20, 1442-1449, 1994.
110. Chiaramonte M., Stroffolini T., Caporaso N., Coppola R., Craxi A., Gaeta GB., Sagnelli E., Zanetti AR.: Hepatitis C virus infection in Italy: a multicentric seroepidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver). Ital J Gasiroenterol, 23, 555-558, 1991.
111. Osella AR., Misciagna G., Leone A., Di Leo A., Fiore G.: Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol, 27, 30-35, 1997.
112. Dubois F., Desenclos JC., Mariotte N., Goudeau A., the Collaborative Study Group: Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology, 25, 1490-1496, 1997.
113. Davis GL., Albright JE., Cook S., Rosenberg D.:Projecting the future healthcare burden from hepatitis C in the United States (abstract). Hepatology, 28, 390A, 1998.
114. Sagmeister M., Renner EL., Müllhaupt B., Wang JB.: Modeling of Hepatitis C in Switzerland: Prevalence, Future Epidemic and Costs. Schweiz Med. Wschr, in press (Abstract).